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ABSTRACT  
Increase in the mortality and morbidity in pleural infection is a concern worldwide due to increasing resistant Gram negative pathogens 
like Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella species. Rise of pneumonia due to K. pneumoniae, is more likely 
observed in alcoholics, diabetics, hospitalized and patients receiving mechanical ventilation. In the present study, we discuss a case of a 
59 year old male patient with pulmonary effusion infected with extended spectrum beta-lactamases (ESBL) producing K. pneumoniae 
with co-morbidities of uncontrolled Type II diabetes mellitus (DM), hypertension and coronary artery disease (CAD), treated with a newer 
antibiotic adjuvant entity: Elores (ceftriaxone/sulbactam/disodium edetate) and recovered well. 
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INTRODUCTION 
The incidence of pleural infection continues to rise worldwide. 
Pleural infections significantly increase the morbidity and 
mortality. Reported mortality rate in adults is up to 20%. The 
accumulation of fluid in the pleural space is a common 
manifestation of a wide range of diseases.[1] 
The bacteria isolated from infected pleural effusion vary 
significantly between community and hospital-acquired 
infections. In India, microbial causes of pleural infections are 
mainly caused by Gram-negative pathogens. Isolation of aerobic 
Gram-negative bacteria from pleural fluid cultures range from 
84.54% to 95.6%.[2] Common Gram-negative organisms 
identified in pleural infections are Acinetobacter spp., Klebsiella 
spp and Pseudomonas aeruginosa.[3] Klebsiella pneumoniae is 
the predominant bacterium associated with Lower Respiratory 
Tract Infections (LRTI) in the developing nations like India.[4] 
Pneumonia due to K.pneumoniae is more common in alcoholics, 
diabetics, hospitalized and patients on prolonged mechanical 
ventilation.[5] Diabetes mellitus is a major risk factor for K. 
pneumoniae infection and relates to more pulmonary 
complications than non-diabetic.[6] 
Local evolution of Multi-Drug Resistant (MDR) bacteria due to 
persistent exposure of multiple antibiotics combined with 
horizontal gene transfer leads to rapid and widespread of 
resistant genomes like Extended-Spectrum β-lactamases 
(ESBLs). The prevalence of various beta-lactamases in the 
Gram-negative bacteria is alarmingly high, with 8 to 80% of 
ESBL production.[2, 7] K. pneumoniae and Escherichia coli 
remain the major ESBL-producing organisms isolated 
worldwide.[7] 
The isolation of aerobic Gram-negative bacteria or multiple 
pathogens from pleural fluid is associated with poor prognosis 
and requires a more aggressive broad spectrum antimicrobial 
chemotherapy.[2, 8] Moreover, increasing resistance to beta 
lactam group of antibiotics with/without beta lactamase 
inhibitor combination, has created a therapeutic challenge in 
treating MDR ESBL producing organisms due to production of 
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latest generation of beta lactamase enzymes which are not 
neutralized by tazobactam and clavulanic acid. Hence, a need of 
a newer antibiotic with a novel approach against ESBL 
producing pathogens in pleural infections is highlighted. 
Here, we are presenting a case of pneumonia with multiloculated 
left pleural effusion caused by ESBL producing Klebsiella 
pneumoniae in patient with uncontrolled Type-2 diabetics 
treated effectively with an Antibiotic Adjuvant Entity: Elores. 
CASE REPORT 
A 59 years male patient, known case of hypertension, 
uncontrolled Type II DM, old CVA, CAD was admitted in a 
private hospital with chief complaints of left side chest pain, 
cough, fever and breathlessness since 2-3 days, treated for CAD 
with minor improvements. Patient was referred to our hospital 
for further management. On general examination patient was 
conscious oriented but general condition was poor and 
dyspnoeic. His blood pressure was 140/80 mmHg, temperature 
98.40o F, pulse rate 102/min, respiratory rate 24/min and SPO2 
98% and random blood sugar level on glucometer was 310 
mg/dL. On systemic examination CVS S1S2 were normal, 
respiratory system showed decreased air entry left side with 
creps, while abdominal was soft and CNS was non remarkable. 
Patient was investigated. Haematological report showed 
deranged values for haemoglobin 9.7 g/dL(low), total leukocyte 
count (TLC) 16.9 x103/mm3 (high), platelet count 4.98 x 
103/mm3 (high), erythrocyte sedimentation rate (ESR) 35 mm/h 
(high) and  serum creatinine 1.68 mg/dL (high). Chest X ray and 
High-resolution computed tomography (HRCT) scan of chest 
showed left lower zone collapsed/consolidation associated with 
multiloculated left pleural effusion and minimal right pleural 
thickening. Left upper lobe and right lung surfaces were lined 
with fibrotic bands. Contrast-enhanced computed tomography 
(CECT) was done to rule out empyema. Based on the clinical 
and lab findings, medicine, chest and diabetologist opinion was 
taken and followed. Ultrasonography (USG) guided pleural 
aspiration was done and sample sent for culture and sensitivity. 
Patient was empirically put on intravenous piperacillin-
tazobactam 4.5 g TDS, levofloxacin 750 mg along with insulin 
infusion, nebulisation and other supportive measures. 
Laboratory reports of pleural effusion showed Glucose: 08 g/dL, 
Protien: 2.44 g/dL, Albumin: 0.4 g/dL, Adenosine Deaminase 
(ADA): 70.15 g/dL, TLC: 3000µl, Neutrophils: 90 and 
lymphocytes: 10. Culture sensitivity report showed ESBL 
producing Klebsiella pneumoniae, resistant to piperacillin-
tazobactam, Meropenem and Imipenem-cilastatin, but sensitive 
for Elores (Ceftriaxone/Sulbactam/Disodium edetate). Patients 
general condition deteriorated even after 3 days of antimicrobial 
therapy, with haemoglobin 9.4 g/dL, TLC 10.9x103/mm3, ESR 
48 mm/h, platelet count 5.48x103/mm3 and serum creatinine 
1.66 mg/dL were not improved. 
Based on the sensitivity and biochemical parameters, antibiotic 
therapy with Piperacillin-tazobactam and levofloxacin was 
stopped and Elores 3g BID with 90 minutes infusion was 
initiated along with other supportive treatment. Elores treatment 
was continued for 7 days. Patient condition gradually improved, 
chest X ray on the 7th day after Elores treatment showed gross 
resolution and improvement. Patient was discharged from the 
hospital on oral treatment with follow up advised after 7 days. 
Patient responded well to the treatment. 
DISCUSSION 
Pleural infections are associated with significant morbidity and 
mortality.  Klebsiella pneumoniae is the predominant bacterium 
associated with lower respiratory tract infections in India, 
especially in patients with diabetic, hospitalized and receiving 
mechanical ventilation.[4] The rising incidence and prevalence  
of K. pneumoniae can be attributed to increased resistant 
mechanism to antibiotics: hyperproduction of ESBL enzymes, 
porin-deficient mutant development, hyperactivity of efflux 
pump and delay in appropriate antimicrobial treatment.[9] 
Furthermore, with increasing prevalence and resistance to 
expanded spectrum cephalosporins, ESBL producing pathogens 
create a major therapeutic challenge in clinical setups. 
Klebsiella pneumoniae and Escherichia coli remain the major 
ESBL-producing organisms isolated worldwide. The percentage 
of ESBL producing organisms ranging from 4% to 83% in 
India.[2] 
In patients with diabetes, pulmonary complications are 
relatively more as compared to non-diabetics. Disturbances in 
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acquired immunity, alteration in the function of capillary 
endothelium and the rigidity of red blood cells may affect the 
hosts’ ability to combat infections.[10] Diabetes mellitus is 
known as a major risk factor for K. pneumoniae infection.[10, 11] 
Pleural effusions can be either free flowing or loculated. 
Loculation of pleural fluid develop next to the occurrence of 
visceral-to-parietal adhesions, blocking fluid from falling to the 
dependent portion of the pleural cavity thereby leading to 
development of loculations in any part of the pleural cavity. In 
the present case, patient presented with left lower zone collapse/ 
consolidation associated with multiloculated left pleural 
effusion and minimal right pleural thickening. Diagnosis by 
HRCT and/or CECT is performed to rule out empyema, as 
treatment for empyema requires chest tube drainage in addition 
to antibiotic therapy.[12] 
Patients with suspected pleural infection should receive 
appropriate broad spectrum antibiotic therapy from the time of 
first review based on local prescribing guidelines, resistance 
patterns and culture sensitivity report.[13] 
In the present case patient was empirically put on intravenous 
piperacillin-tazobactam 4.5 g TDS, levofloxacin 750mg (based 
on hospital antibiogram) along with insulin infusion, 
nebulisation and other supportive measures. USG guided pleural 
aspiration was done, culture and sensitivity reports showed 
ESBL producing K.pnemoniae, resistant to piperacillin-
tazobactam with sensitivity for Elores. Based on the clinical 
radiological and laboratory findings patient was diagnosed as 
Type II diabetic, pneumonia with multiloculated left pleural 
effusion caused by ESBL producing K. pneumoniae. Post 3 days 
of empiric therapy the antibiotic was switched to Elores 1.5g 
B.D dose with 90 minutes infusion on the basis of culture and 
sensitivity report. 
Elores is an Antibiotic Adjuvant Entity with a novel 
combination of Ceftriaxone/Sulbactam/ Disodium edetate, can 
combat antimicrobial resistance produced by bacteria. The 
reason for increased susceptibility of Elores is synergistic 
activity of ceftriaxone, sulbactam and disodium edetate, which 
makes more susceptible it towards ESBLs and MBLs producing 
organisms. 
In an in-vitro study done on K.pnemoniae  strains collected from 
North India,  Elores showed a significant susceptibility against 
ESBLs and MBLs.[14] This is because of Elores activity against 
down regulation of ESBL/MBL producing genes, increased 
bacterial cell permeability, down regulation of efflux pump over 
expression and ability to break bacterial biofilms.[15] 
Phase-III clinical trial on Elores reported clinical cure rate of 
91.30% (42/46)  and 97.05% (33/34) in LRTI patients.[16] Sahu 
et al., reported 82% sensitive and intermediate sensitive to 
ESBL producing clincal strains of K. pneumoniae majority 
isolates from sputum, urine, tissue and pus.[15] 
CONCLUSION 
Rise in the incidence of pleural infection worldwide by multi-
drug resistant ESBL producing K. pneumoniae can be attributed 
to the higher efficacy of the pathogen to transfer resistance 
factors from one bacterium to other. Patients with co-
morbidities like diabetes, increase the chances for pulmonary 
complications. Early recognition and diagnosis with prompt 
broad spectrum antibiotic improves the condition of patient. We 
have presented here a case of MDR ESBL producing K. 
pneumoniae in Type II diabetic patient treated with a newer 
antibiotic adjuvant entity: Elores, which showed promising 
results, both in safety and efficacy. Elores could be considered 
as an effective solution for treating Gram negative ESBL 
producing pathogens where first line of antibiotics fail to 
respond.   
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